Database of prostate cancer patients at Institut Paoli-Calmettes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study involves the creation of a comprehensive database for patients diagnosed with prostate cancer at the Institut Paoli-Calmettes. The database aims to collect and analyze clinical data to better understand the disease and improve patient outcomes. By gathering detailed information on patient demographics, treatment responses, and disease progression, the study seeks to facilitate future research and enhance clinical practices in prostate cancer management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Prostatic cancer

Exclusion Criteria:

* Non applicable

Where it's running

• Institut Paoli-Calmettes
  Marseille, Bouches-du Rhône, France Recruiting

Study contacts

• Study coordinator: Dominique Genre, MD
• Email: drci.up@ipc.unicancer.fr
• Phone: 0033491223778

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• JNJ-101556143 plus Best Supportive Care for metastatic prostate cancer

  This study tests whether adding JNJ-101556143 to standard supportive care helps people with metastatic, hormone-resistant prostate cancer live longer than those who receive placebo plus supportive care.

  Recruiting at 4 sites Phase 3 Janssen Research & Development, LLC · El Paso, Texas and 3 other locations · NCT07906717

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Testing JNJ-101556143 in men with advanced prostate cancer that no longer responds to hormone therapy

  This study tests JNJ-101556143 in men with metastatic, hormone-resistant prostate cancer to see if tumors shrink or disappear.

  Recruiting at 14 sites Phase 2 Janssen Research & Development, LLC · Largo, Florida and 13 other locations · NCT07832292

• New treatment option for advanced prostate cancer using JNJ-98768111

  A first-in-human study tests JNJ-98768111 to see how safe it is and find the best dose for people with advanced prostate cancer who have already tried other therapies.

  Recruiting at 6 sites Phase 1 Janssen Research & Development, LLC · Sarasota, Florida and 5 other locations · NCT07746713

• Benchmarking AI language models against tumor boards for oncology treatment decisions

  This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Boulogne-Billancourt and 4 other locations · NCT07739121

• FX-111 safety and pharmacokinetics in metastatic castration-resistant prostate cancer

  This study tests whether FX-111 is safe and can help treat metastatic castration-resistant prostate cancer in adult men.

  Recruiting at 7 sites Phase 1 Flare Therapeutics Inc. · Los Angeles, California and 9 other locations · NCT07719361

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.